Similarly, it was announced by Xiong et al. that miR‐145 inhibited intrahepatic cholangiocarcinoma (ICC) proliferation by targeting NUAK1 and its downstream effectors, demonstrating significance in clinical diagnosis and targeted therapy of ICC 16. The gene discussed is NUAK1; the disease is intrahepatic cholangiocarcinoma.